M
Matthias R. Bauer
Researcher at Laboratory of Molecular Biology
Publications - 32
Citations - 1452
Matthias R. Bauer is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Mutant & Virtual screening. The author has an hindex of 16, co-authored 30 publications receiving 1008 citations. Previous affiliations of Matthias R. Bauer include AstraZeneca & University of Tübingen.
Papers
More filters
Journal ArticleDOI
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease
Christophe Lo Bianco,Bernard L. Schneider,Matthias R. Bauer,Ali Sajadi,Alexis Brice,Takeshi Iwatsubo,Patrick Aebischer +6 more
TL;DR: Results indicate that parkin gene therapy may represent a promising candidate treatment for PD, with significant reductions in alpha-synuclein-induced neuropathology, and a key role for parkin in the genesis of Lewy bodies.
Journal ArticleDOI
Evaluation and optimization of virtual screening workflows with DEKOIS 2.0--a public library of challenging docking benchmark sets.
TL;DR: The previously introduced DEKOIS methodology is improved with enhanced physicochemical matching, now including the consideration of molecular charges, as well as a more sophisticated elimination of latent actives in the decoy set (LADS).
Journal ArticleDOI
Put a ring on it: application of small aliphatic rings in medicinal chemistry.
Matthias R. Bauer,Paolo Di Fruscia,Simon C. C. Lucas,Iacovos N Michaelides,Jennifer E. Nelson,R. Ian Storer,Benjamin C Whitehurst +6 more
TL;DR: A historical perspective and comparative up to date overview of commonly applied small rings, exemplifying key principles with recent literature examples and potential hazards and liabilities are illustrated and explained.
Journal ArticleDOI
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
TL;DR: Certain activated electrophilic 2-sulfonylpyrimidines are a new class of thiol-reactive anticancer agents that are especially effective in killing cancer cells with mutant or inactivated p53 or impaired reactive oxygen species detoxification and have relatively low cytotoxicity toward normal cells.
Journal ArticleDOI
Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein-Ligand Complexes.
Matthias R. Bauer,Mark D. Mackey +1 more
TL;DR: This work presents a fast and efficient tool to calculate and visualize the electrostatic complementarity (EC) of protein-ligand complexes and demonstrates that the EC method can visualize, rationalize, and predict electrostatically driven ligand affinity changes and help to predict compound selectivity.